Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News How a proenzyme-based approach from Propanc Biopharma tests the limits of current solid tumor paradigms Can a proenzyme therapy reshape solid tumor treatment models? Explore what Propanc Biopharma’s PRP strategy signals for oncology markets. bySoujanya RaviFebruary 7, 2026